{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:17:05Z","timestamp":1775470625077,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,7]]},"DOI":"10.7759\/cureus.32286","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T13:29:00Z","timestamp":1670419740000},"source":"Crossref","is-referenced-by-count":5,"title":["The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Chinmayi Sree","family":"Boddepalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Dheeraj","family":"Gutlapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsi Krishna","family":"Lavu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Abdelwahab Mohamed Abdelwahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruimin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Potla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushen","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif","family":"AlQabandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savitri Aninditha","family":"Nandula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"2022 annual data report\r\n. (2020). Accessed. November 2022: https:\/\/adr.usrds.org\/2020\/reference-tables."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2021.02.003","article-title":"Evaluation of clinical and anti-diabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: data from a Mediterranean population database","volume":"15","author":"Mata-Cases M","year":"2021","unstructured":"Mata-Cases M, Franch-Nadal J, Real J, Vlacho B, G\u00f3mez-Garc\u00eda A, Mauricio D. Evaluation of clinical and anti-diabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: data from a Mediterranean population database. Prim Care Diabetes. 2021, 15:588-95. 10.1016\/j.pcd.2021.02.003","journal-title":"Prim Care Diabetes"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/snep.2002.2002.35962","article-title":"Chronic kidney disease in the United States: an underrecognized problem","volume":"22","author":"Obrador GT","year":"2002","unstructured":"Obrador GT, Pereira BJ, Kausz AT. Chronic kidney disease in the United States: an underrecognized problem. Semin Nephrol. 2002, 22:441-8. 10.1053\/snep.2002.2002.35962","journal-title":"Semin Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler AI","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003, 63:225-32. 10.1046\/j.1523-1755.2003.00712.x","journal-title":"Kidney Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.27.2.82","article-title":"A brief history of the development of diabetes medications","volume":"27","author":"White JR Jr","year":"2014","unstructured":"White JR Jr. A brief history of the development of diabetes medications. Diabetes Spectr. 2014, 27:82-6. 10.2337\/diaspect.27.2.82","journal-title":"Diabetes Spectr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2231","article-title":"Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4","volume":"41","author":"Lalau JD","year":"2018","unstructured":"Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018, 41:547-53. 10.2337\/dc17-2231","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus","volume":"147","author":"Bolen S","year":"2007","unstructured":"Bolen S, Feldman L, Vassy J, et al.. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007, 147:386-99. 10.7326\/0003-4819-147-6-200709180-00178","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801223380415","article-title":"Lactic acidosis in patients with diabetes treated with metformin","volume":"338","author":"Misbin RI","year":"1998","unstructured":"Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998, 338:265-6. 10.1056\/NEJM199801223380415","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.6.925","article-title":"Incidence of lactic acidosis in metformin users","volume":"22","author":"Stang M","year":"1999","unstructured":"Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999, 22:925-7. 10.2337\/diacare.22.6.925","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01617.x","article-title":"Metformin therapy in patients with chronic kidney disease","volume":"14","author":"Duong JK","year":"2012","unstructured":"Duong JK, Roberts DM, Furlong TJ, et al.. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab. 2012, 14:963-5. 10.1111\/j.1463-1326.2012.01617.x","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler WC","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002, 346:393-403. 10.1056\/NEJMoa012512","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.4.977","article-title":"Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program","volume":"26","author":"Diabetes Prevention Program Research Group","year":"2003","unstructured":"Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003, 26:977-80. 10.2337\/diacare.26.4.977","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0097-z","article-title":"The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)","volume":"49","author":"Ramachandran A","year":"2006","unstructured":"Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006, 49:289-97. 10.1007\/s00125-005-0097-z","journal-title":"Diabetologia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2020.09.016","article-title":"Glucose-lowering medication use in CKD: analysis of US Medicare beneficiaries between 2007 and 2016","volume":"3","author":"Zhao JZ","year":"2021","unstructured":"Zhao JZ, Weinhandl ED, Carlson AM, St Peter WL. Glucose-lowering medication use in CKD: analysis of US Medicare beneficiaries between 2007 and 2016. Kidney Med. 2021, 3:173-182.e1. 10.1016\/j.xkme.2020.09.016","journal-title":"Kidney Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2289","article-title":"Use of antidiabetic drugs in the U.S., 2003-2012","volume":"37","author":"Hampp C","year":"2014","unstructured":"Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014, 37:1367-74. 10.2337\/dc13-2289","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020, 43:S98-S110. 10.2337\/dc20-S009","journal-title":"Diabetes Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard HW","year":"2009","unstructured":"Rodbard HW, Jellinger PS, Davidson JA, et al.. Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009, 15:540-59. 10.4158\/EP.15.6.540","journal-title":"Endocr Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022768","article-title":"Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017","volume":"8","author":"Wilkinson S","year":"2018","unstructured":"Wilkinson S, Douglas I, Stirnadel-Farrant H, Fogarty D, Pokrajac A, Smeeth L, Tomlinson L. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017. BMJ Open. 2018, 8:e022768. 10.1136\/bmjopen-2018-022768","journal-title":"BMJ Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002742","article-title":"COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology","volume":"16","author":"Dekkers OM","year":"2019","unstructured":"Dekkers OM, Vandenbroucke JP, Cevallos M, Renehan AG, Altman DG, Egger M. COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. PLoS Med. 2019, 16:e1002742. 10.1371\/journal.pmed.1002742","journal-title":"PLoS Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup DF","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, et al.. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000, 283:2008-12. 10.1001\/jama.283.15.2008","journal-title":"JAMA"},{"key":"ref21","unstructured":"Newcastle - Ottawa quality assessment scale. (2012). Accessed. November, 2022: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/nosgen.pdf."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.07.017","article-title":"A safety comparison of metformin vs. sulfonylurea initiation in patients with type 2 diabetes and chronic kidney disease: a retrospective cohort study","volume":"95","author":"Whitlock RH","year":"2020","unstructured":"Whitlock RH, Hougen I, Komenda P, Rigatto C, Clemens KK, Tangri N. A safety comparison of metformin vs. sulfonylurea initiation in patients with type 2 diabetes and chronic kidney disease: a retrospective cohort study. Mayo Clin Proc. 2020, 95:90-100. 10.1016\/j.mayocp.2019.07.017","journal-title":"Mayo Clin Proc"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-4219-3","article-title":"Mortality associated with metformin versus sulfonylurea initiation: a cohort study of veterans with diabetes and chronic kidney disease","volume":"33","author":"Marcum ZA","year":"2018","unstructured":"Marcum ZA, Forsberg CW, Moore KP, de Boer IH, Smith NL, Boyko EJ, Floyd JS. Mortality associated with metformin versus sulfonylurea initiation: a cohort study of veterans with diabetes and chronic kidney disease. J Gen Intern Med. 2018, 33:155-65. 10.1007\/s11606-017-4219-3","journal-title":"J Gen Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12764","article-title":"Metformin-associated risk of acute dialysis in patients with type 2 diabetes: a nationwide cohort study","volume":"18","author":"Carlson N","year":"2016","unstructured":"Carlson N, Hommel K, Olesen JB, et al.. Metformin-associated risk of acute dialysis in patients with type 2 diabetes: a nationwide cohort study. Diabetes Obes Metab. 2016, 18:1283-7. 10.1111\/dom.12764","journal-title":"Diabetes Obes Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019211","article-title":"Hospitalization for heart failure among patients with diabetes mellitus and reduced kidney function treated with metformin versus sulfonylureas: a retrospective cohort study","volume":"10","author":"Richardson TL Jr","year":"2021","unstructured":"Richardson TL Jr, Hackstadt AJ, Hung AM, et al.. Hospitalization for heart failure among patients with diabetes mellitus and reduced kidney function treated with metformin versus sulfonylureas: a retrospective cohort study. J Am Heart Assoc. 2021, 10:e019211. 10.1161\/JAHA.120.019211","journal-title":"J Am Heart Assoc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2391","article-title":"Hospitalization for lactic acidosis among patients with reduced kidney function treated with metformin or sulfonylureas","volume":"43","author":"Chu PY","year":"2020","unstructured":"Chu PY, Hackstadt AJ, Chipman J, et al.. Hospitalization for lactic acidosis among patients with reduced kidney function treated with metformin or sulfonylureas. Diabetes Care. 2020, 43:1462-70. 10.2337\/dc19-2391","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3625","article-title":"Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study","volume":"354","author":"van Dalem J","year":"2016","unstructured":"van Dalem J, Brouwers MC, Stehouwer CD, et al.. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ. 2016, 354:i3625. 10.1136\/bmj.i3625","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3432","article-title":"Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control","volume":"22","author":"Hung AM","year":"2013","unstructured":"Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, Griffin MR. Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Pharmacoepidemiol Drug Saf. 2013, 22:623-31. 10.1002\/pds.3432","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.444","article-title":"Comparative effectiveness of incident oral antidiabetic drugs on kidney function","volume":"81","author":"Hung AM","year":"2012","unstructured":"Hung AM, Roumie CL, Greevy RA, et al.. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int. 2012, 81:698-706. 10.1038\/ki.2011.444","journal-title":"Kidney Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.12.2244","article-title":"Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes","volume":"25","author":"Johnson JA","year":"2002","unstructured":"Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002, 25:2244-8. 10.2337\/diacare.25.12.2244","journal-title":"Diabetes Care"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.11","article-title":"Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway","volume":"77","author":"Morales AI","year":"2010","unstructured":"Morales AI, Detaille D, Prieto M, et al.. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int. 2010, 77:861-9. 10.1038\/ki.2010.11","journal-title":"Kidney Int"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-9-201211060-00003","article-title":"Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study","volume":"157","author":"Roumie CL","year":"2012","unstructured":"Roumie CL, Hung AM, Greevy RA, et al.. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012, 157:601-10. 10.7326\/0003-4819-157-9-201211060-00003","journal-title":"Ann Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.09.001","article-title":"Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study","volume":"23","author":"Cheng YY","year":"2014","unstructured":"Cheng YY, Leu HB, Chen TJ, Chen CL, Kuo CH, Lee SD, Kao CL. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. J Stroke Cerebrovasc Dis. 2014, 23:e99-105. 10.1016\/j.jstrokecerebrovasdis.2013.09.001","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007611","article-title":"Association between stroke risk and metformin use in hemodialysis patients with diabetes mellitus: a nested case-control study","volume":"6","author":"Chien LN","year":"2017","unstructured":"Chien LN, Chou CL, Chen HH, et al.. Association between stroke risk and metformin use in hemodialysis patients with diabetes mellitus: a nested case-control study. J Am Heart Assoc. 2017, 6:10.1161\/JAHA.117.007611","journal-title":"J Am Heart Assoc"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study","volume":"178","author":"Lazarus B","year":"2018","unstructured":"Lazarus B, Wu A, Shin JI, et al.. Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study. JAMA Intern Med. 2018, 178:903-10. 10.1001\/jamainternmed.2018.0292","journal-title":"JAMA Intern Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2017.03.005","article-title":"The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: what to expect from new oral hypoglycemic agents","volume":"11 Suppl 1","author":"Di Lullo L","year":"2017","unstructured":"Di Lullo L, Mangano M, Ronco C, et al.. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: what to expect from new oral hypoglycemic agents. Diabetes Metab Syndr. 2017, 11 Suppl 1:S295-305. 10.1016\/j.dsx.2017.03.005","journal-title":"Diabetes Metab Syndr"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020122","article-title":"The current and potential therapeutic use of metformin\u2014the good old drug","volume":"14","author":"Drzewoski J","year":"2021","unstructured":"Drzewoski J, Hanefeld M. The current and potential therapeutic use of metformin\u2014the good old drug. Pharmaceuticals (Basel). 2021, 14:10.3390\/ph14020122","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3042","article-title":"Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes","volume":"98","author":"Currie CJ","year":"2013","unstructured":"Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013, 98:668-77. 10.1210\/jc.2012-3042","journal-title":"J Clin Endocrinol Metab"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3413","article-title":"Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease","volume":"22","author":"Masica AL","year":"2013","unstructured":"Masica AL, Ewen E, Daoud YA, et al.. Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2013, 22:413-22. 10.1002\/pds.3413","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1450","article-title":"Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care","volume":"352","author":"Hippisley-Cox J","year":"2016","unstructured":"Hippisley-Cox J, Coupland C. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. BMJ. 2016, 352:i1450. 10.1136\/bmj.i1450","journal-title":"BMJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/104857-the-effectiveness-and-safety-of-metformin-compared-to-sulfonylureas-in-diabetic-nephropathy-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:40Z","timestamp":1707507880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/104857-the-effectiveness-and-safety-of-metformin-compared-to-sulfonylureas-in-diabetic-nephropathy-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.32286","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,7]]}}}